

## SUPPLEMENTARY FIGURE LEGENDS

**Table 1.** Ectopic expression of green fluorescent protein (GFP)-tagged Gpc-1:  
**Primers used for amplification of cDNA for introduction into pEGFP C1**

1.	hGPC 1-92	5'-TAAT <i>GC TAGC</i> GCC GCC ACC ATG GAG CTC CGG GCC CGA-3' 5'-TAA <i>ACC GGT</i> CTC CGG CTC TTG CTG GC-3'
2.	hGPC 91- 1677	5'-TAA TAA <i>GCT TCA</i> AGC TGC GGC GAG GTC CGC CAG-3' 5'-TT <i>GAA TTC</i> TTA CCG CCA CCG GGG CCT GGC TAC-3'

Restriction enzyme cleavage sites are marked in italics.

### Mutagenic primer to disrupt Kozak sequence in EGFP

5'-CACCGGTCGCCACTGTAGTGAGCAAGGGCGAG-3'

**Fig. S1.** Schematic structures of amyloid precursor protein (APP), glypican-1 (Gpc-1), their degradation products and possible HS-A $\beta$  conjugates. **(a)** APP is a type I transmembrane protein with a large N-terminal ectodomain, a short C-terminal cytosolic portion and an A $\beta$  segment (black box) that is partially embedded in the cell membrane (grey box).  $\beta$ -Secretase cleavage generates **(b)** a C-terminal fragment (expanded) containing closely clustered  $\gamma$ -secretase cleavage sites. Subsequent cleavage at these sites generates **(c)** A $\beta$  peptides (mainly A $\beta$ 40/42). Antibodies used to detect the C-terminus of APP and the A $\beta$  region are indicated. **(d)** Gpc-1 is lipid-anchored (oval with two short rods), carries three heparan sulfate (HS) chains and has a large globular N-terminal domain (grey) (Svensson et al., 2009). Conserved Cys residues in the globular part are S-nitrosylated (SNO) by endogenously formed NO in a Cu(II)-dependent redox reaction. Cu(II)-loaded APP supports this reaction (Cappai et al., 2005). Gpc-1 can be endocytosed and recycled. An endogenous reducing agent present in endosomes (Fivaz et al., 2002; Mani et al., 2006), or exogenously supplied ascorbate, releases NO from Cys (SH). NO cleaves heparan sulfate at GlcNH $_3^+$  units (GN, see left blow-up), generating anhydromannose-containing oligosaccharides (AM) which contain a free aldehyde (see right blow-up). **(e)** The free aldehyde of the reducing terminal anhydromannose (anMan) in the released HS degradation products can form a Schiff base with amino groups in a reversible reaction. Stable HS-A $\beta$  conjugates may be formed by reduction or via various rearrangements. The free aldehyde can also be reduced, generating a terminal anhydromannitol (anManOH) residue (containing -CH $_2$ OH). The anMan-specific mAb AM was raised against partially deaminatively cleaved heparin (Fragmin<sup>R</sup>). The principal epitope should be a tetrasaccharide sequence IdoA(2-OSO $_3$ )-GlcNSO $_3$ (6-OSO $_3$ )-IdoA(2-OSO $_3$ )-anMan(6-OSO $_3$ ), where GlcNSO $_3$  is N-sulfated glucosamine and IdoA is L-iduronic acid (Pejler et al., 1988). Similar sequences have been found in HS associated with amyloid deposits (Smits et al., 2010).

**Fig. S2.** Expression of APP in mouse embryonic fibroblasts (MEF) from Tg2576 (Tg) and wild-type (non Tg) mice as demonstrated by SDS-PAGE and western blotting using mAb WO2.

**Fig. S3.** Localization of anMan-immunoreactivity in Tg2576 fibroblasts. The immunofluorescence microscopy images were obtained after staining cultures of Tg2576 fibroblasts with the anMan-specific mAb (AM, green) and **(a)** a polyclonal anti-Rab7 (red) or **(b)** LysoTrackerRed (LTR, red). Scale bar: 20  $\mu$ m.

### References

- Cappai R., Cheng F., Ciccotosto G.D., Needham, B.E., Masters C.L., Multhaup G., Fransson L.-Å. and Mani K. (2005) The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo. *J. Biol. Chem.* **280**, 13913-13920.

- Fivaz M., Vilbois, F., Thurnheer, S., Pasquali, C., Abrami, L., Bickel, P.E., Parton, R.G. and van der Groot, F.G. (2002) Differential sorting and fate of endocytosed GPI-anchored proteins. *EMBO J.* **21**, 3989-4000
- Mani K., Cheng F. and Fransson L.-Å. (2006) Constitutive and vitamin C-induced, NO-catalyzed release of heparan sulfate from recycling glypican-1 in late endosomes. *Glycobiology* **16**, 1251-1261.
- Pejler G., Lindahl U., Larm O., Scholander E., Sandgren E. and Lundblad, A. (1988) Monoclonal antibodies specific for oligosaccharides prepared by partial nitrous acid deamination of heparin. *J.Biol. Chem.* **263**, 5197-5201.
- Smits N.C., Kurup S., Rops A.L., Ten Dam G.B., Massuger L.F., Hafmans T., Turnbull J.E., Spillman D., Li J.P., Kennel S.J., Wall J.S., Shworak N.W., Dekhuijzen P.N., van der Vlag J. and van Kuppevelt T.H. (2010) The heparan sulfate motif (GlcNS6S-IdoA2S)<sub>3</sub>, common in heparin, has a strict topography and is involved cell behaviour and disease.
- Svensson, G., Linse, S. and Mani, K. (2009) Chemical and thermal unfolding of glypican-1: protective effect of heparan sulfate against heat-induced irreversible aggregation. *Biochemistry* **48**, 9994-10004




Fig.S1




Fig. S2




Fig. S3